DOA
CORT icon

D'Orazio & Associates’s Corcept Therapeutics CORT Stock Holding History

D'Orazio & Associates’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-250
Closed -$5K – 297
2017
Q4 		$5K Buy
+250
New +$4.53K ﹤0.01% 266

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D'Orazio & Associates's CORT Position: Q1 2018 in Review

D'Orazio & Associates sold out of Corcept Therapeutics (CORT) in Q1 2018, closing a stake of 250 shares — an estimated $5K sold.

D'Orazio & Associates first reported a position in CORT in Q4 2017 and held it in 1 quarter. The position peaked at $5K in Q4 2017. 212 funds tracked by Wall St. Rank hold CORT as of Q1 2018.

  • D'Orazio & Associates reported no remaining Corcept Therapeutics position as of Q1 2018 after selling out during the quarter.
  • D'Orazio & Associates sold 250 Corcept Therapeutics shares in Q1 2018, an estimated $5K.
  • D'Orazio & Associates first reported a position in Corcept Therapeutics in Q4 2017 and held it in 1 quarter.
  • D'Orazio & Associates's Corcept Therapeutics position peaked at $5K in Q4 2017.
  • 212 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2018.

Based on D'Orazio & Associates's 13F filing for Q1 2018, filed 4 May 2018.